Suppr超能文献

tau结构域特异性抗体和静脉注射免疫球蛋白对tau聚集及聚集体降解的影响

Effects of tau domain-specific antibodies and intravenous immunoglobulin on tau aggregation and aggregate degradation.

作者信息

Esteves-Villanueva Jose O, Trzeciakiewicz Hanna, Loeffler David A, Martić Sanela

机构信息

Department of Chemistry, Oakland University , 2200 North Squirrel Road, Rochester, Michigan 48309, United States.

出版信息

Biochemistry. 2015 Jan 20;54(2):293-302. doi: 10.1021/bi501272x. Epub 2015 Jan 6.

Abstract

Tau pathology, including neurofibrillary tangles, develops in Alzheimer's disease (AD). The aggregation and hyperphosphorylation of tau are potential therapeutic targets for AD. Administration of anti-tau antibodies reduces tau pathology in transgenic "tauopathy" mice; however, the optimal tau epitopes and conformations to target are unclear. Also unknown is whether intravenous immunoglobulin (IVIG) products, currently being evaluated in AD trials, exert effects on pathological tau. This study examined the effects of anti-tau antibodies targeting different tau epitopes and the IVIG Gammagard on tau aggregation and preformed tau aggregates. Tau aggregation was assessed by transmission electron microscopy and fluorescence spectroscopy, and the binding affinity of the anti-tau antibodies for tau was evaluated by enzyme-linked immunosorbent assays. Antibodies used were anti-tau 1-150 ("D-8"), anti-tau 259-266 ("Paired-262"), anti-tau 341-360 ("A-10"), and anti-tau 404-441 ("Tau-46"), which bind to tau's N-terminus, microtubule binding domain (MBD) repeat sequences R1 and R4, and the C-terminus, respectively. The antibodies Paired-262 and A-10, but not D-8 and Tau-46, reduced tau fibrillization and degraded preformed tau aggregates, whereas the IVIG reduced tau aggregation but did not alter preformed aggregates. The binding affinities of the antibodies for the epitope for which they were specific did not appear to be related to their effects on tau aggregation. These results confirm that antibody binding to tau's MBD repeat sequences may inhibit tau aggregation and indicate that such antibodies may also degrade preformed tau aggregates. In the presence of anti-tau antibodies, the resulting tau morphologies were antigen-dependent. The results also suggested the possibility of different pathways regulating antibody-mediated inhibition of tau aggregation and antibody-mediated degradation of preformed tau aggregates.

摘要

在阿尔茨海默病(AD)中会出现包括神经原纤维缠结在内的tau蛋白病变。tau蛋白的聚集和过度磷酸化是AD潜在的治疗靶点。给予抗tau抗体可减少转基因“tau蛋白病”小鼠的tau蛋白病变;然而,尚不清楚最佳的tau蛋白表位和靶向构象。目前正在AD试验中评估的静脉注射免疫球蛋白(IVIG)产品是否对病理性tau蛋白有作用也尚不清楚。本研究检测了靶向不同tau蛋白表位的抗tau抗体以及IVIG产品Gammagard对tau蛋白聚集和已形成的tau蛋白聚集体的影响。通过透射电子显微镜和荧光光谱法评估tau蛋白聚集情况,并通过酶联免疫吸附测定法评估抗tau抗体与tau蛋白的结合亲和力。使用的抗体为抗tau 1-150(“D-8”)、抗tau 259-266(“Paired-262”)、抗tau 341-360(“A-10”)和抗tau 404-441(“Tau-46”),它们分别与tau蛋白的N端、微管结合域(MBD)重复序列R1和R4以及C端结合。抗体Paired-262和A-10可减少tau蛋白纤维化并降解已形成的tau蛋白聚集体,而D-8和Tau-46则无此作用,IVIG可减少tau蛋白聚集,但不改变已形成的聚集体。抗体与其特异性表位的结合亲和力似乎与其对tau蛋白聚集的影响无关。这些结果证实,抗体与tau蛋白的MBD重复序列结合可能抑制tau蛋白聚集,并表明此类抗体也可能降解已形成的tau蛋白聚集体。在抗tau抗体存在的情况下,所产生的tau蛋白形态是抗原依赖性的。结果还提示,可能存在不同的途径来调节抗体介导的tau蛋白聚集抑制作用以及抗体介导的已形成tau蛋白聚集体的降解作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验